


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: July 19, 2004

(use as many sheets as necessary)

Complete If Known

Application Number	10/734,638
Filing Date	12/15/2003
First Named Inventor	Philippe ROUANET et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned

Sheet

1

of

1

Attorney Docket Number

029488-0113

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AM	A1	4,973,755		Heumann Pharma GmbH & Co.	11/27/1990	
AM	A2	4,919,937		Pierre MAUVAIS-JARVIS et al.	4/24/1990	
AM	A3	5,904,930		Hexal AG	5/18/1999	
AM	A4	5,945,109		s.w. Patentverwertungs Ges.m.b.H.	8/31/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AM	A5	International Search Report	
AM	A6	Pierre MAUVAIS-JARVIS et al., "trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Administration to Human Breast", Cancer Research, Vol. 46, 3/1986, pp. 1521-1525.	
AM	A7	F. KUTTENN et al., "Principe de l'administration percutanée des antiestrogènes en pathologie mammaire", Contracept. Fertil. Sex. 1991, Vol. 19, No. 2, pp. 165-171.	
AM	A8	I. Simony-Lafontaine et al., "NEOADJUVANT PERCUTANEOUS-4-HYDROXYTAMOXIFEN DECREASES BREAST CANCER CELL PROLIFERATION: A PROSPECTIVE RANDOMIZED IMAGE ANALYSIS STUDY", Analytical Cellular Pathology, vol. 25, no. 5-6 2003, pp. 258-259, XP009030125.	

Examiner Signature


Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub 101, 102, 103, 104, 105, 106, 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 6, 2005

(use as many sheets as necessary)

Complete if Known

Application Number	10/734,638
Filing Date	12/15/2003
First Named Inventor	Philippe ROUANET et al.
Group Art Unit	Unassigned
Examiner Name	1615

Sheet 1 of 3

Attorney Docket Number 029488-0113

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AMC	B1	5,904,930		Hexel AG	5/18/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AMC	B2	J. BARRAT et al., "Effet <i>in vivo</i> de l'administration locale de progestérone sur l'activité mitotique des galactophores humains", J. Gynecol. Obstet. Biol. Reprod. 19: 269-274 1990.	
AMC	B3	Bronaugh & Maibach, "Percutaneous Absorption Drugs-Cosmetics-Mechanisms-Methodology", Marcel Dekker Inc., New York, 1999.	
AMC	B4	Philip CARTHEW et al., "Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat", Arch Toxicol (2001) 75: 375-380.	
AMC	B5	Gerard CHETRITE et al., "Effect of Promegestone, Tamoxifen, 4-Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells", Anticancer Research 13: 931-934 (1993).	
AMC	B6	Eric C. DIETZE et al., "Tamoxifen but Not 4-Hydroxytamoxifen Initiates Apoptosis in p53(-) Normal Human Mammary Epithelial Cells by Inducing Mitochondrial Depolarization", The Journal of Biological Chemistry Vol. 276, No. 7, Issue of February 16, 2001, pp. 5384-5394.	
AMC	B7	I.S. FENTIMAN et al., "Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial", BR. J. SURG. September 1988, Vol. 75, No. 9, pp. 845-846.	
AMC	B8	I.S. FENTIMAN et al., "Studies of tamoxifen in women with mastalgia", The British Journal of Clinical Practice, Supplement 68, Vol. 43, No. 11, November 1989, pp. 34-36.	
AMC	B9	N. GIAMBIAGI et al., "IMMUNOLOGICAL DIFFERENCES BETWEEN THE ESTRADIOL-, TAMXIFEN- AND 4-HYDROXY-TAMOXIFEN-ESTROGEN RECEPTOR COMPLEXES DETECTED BY TWO MONOCLONAL ANTIBODIES", J. Steroid Biochem. Vol. 30, No. 1-6, pp. 213-217, 1988.	

Examiner Signature

Date Considered

4/21/2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

O I P E
JAN 6 2005
JC25

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute Form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Date Submitted: January 6, 2005
(use as many sheets as necessary)

Complete if Known

Application Number	10/734,638
Filing Date	12/15/2003
First Named Inventor	Philippe ROUANET et al.
Group Art Unit	Unassigned
Examiner Name	1615

Sheet 2 of 3 Attorney Docket Number 029488-0113

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AM	B10	V. Craig JORDAN et al., "Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance", Breast Cancer Research and Treatment, 2, pp. 123-138.	
AM	B11	George G.J.M. KUIPER et al., "Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β ", Endocrinology, Vol. 138, No. 3, 1997, pp. 863-870.	
AM	B12	Frédérique KUTTENN et al., "MÉDECINE ET THÉRAPEUTIQUE", C.R. Acad. Sc. Paris, , Série III, No. 12, 1985, 300:457-461.	
AM	B13	Catherine MALET et al., "Tamoxifen and Hydroxytamoxifen Isomers versus Estradiol Effects on Normal Human Breast Cells in Culture", Cancer Research, Vol. 48, No. 24, December 15, 1988, pp. 7193-7199.	
AM	B14	Pierre MAUVAIS-JARVIS et al., "trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Administration to Human Breast", Cancer Research, Vol. 46, March 1986, pp. 1521-1525.	
AMC	B15	David W. ROBERTSON et al., "Synthesis of the E and Z Isomers of the Antiestrogen Tamoxifen and Its Metabolite, Hydroxytamoxifen, in Tritium-Labeled Form", J. Org. Chem., 1982, Vol. 47, No. 12, pp. 2387-2393.	
AMC	B16	David W. ROBERTSON et al., "TAMOXIFEN ANTIESTROGENS, A COMPARISON OF THE ACTIVITY, PHARMACOKINETICS, AND METABOLIC ACTIVATION OF THE C/S AND TRANS ISOMERS OF TAMOXIFEN" Journal of Steroid Biochemistry, Vol. 16, pp. 1-13, (1982).	
AMC	B17	Fabrice SAUVEZ et al., "Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats", Carcinogenesis Vol. 20, No. 5, pp. 843-850 1999.	
AMC	B18	Ashini L. WIJAYARATNE et al., "Comparative Analyses of Mechanistic Differences Among Antiestrogens", Endocrinology, Vol. 140, No. 2, pp. 5828-5840.	
AMC	B19	"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial", The Lancet, Vol. 360, September 14, 2002, pp. 817-824.	
AMC	B20	Carsten SCHLÜTER et al. "The Cell Proliferation-associated Antigen of Antibody Ki-67: A Very Large, Ubiquitous Nuclear Protein with Numerous Repeated Elements, Representing a New Kind of Cell Cycle-maintaining Proteins", The Journal of Cell Biology, Volume 123, 1993, pp. 513-522.	
AMC	B21	Debra J. BEVITT et al., "New Monoclonal Antibodies to Oestrogen and Progesterone Receptors Effective for Paraffin Section Immunohistochemistry", Journal of Pathology, Vol. 183, (1997) pp. 228-232.	
AMC	B22	Lawrence H. BLOCK Ph.D., "Epidermal and Transdermal Drug Delivery", Medicated Topicals, Chapter 44, pp. 836-857.	
AMC	B23	Corinne CHARLIER et al., "Tamoxifen and Its Active Metabolite Inhibit Growth of Estrogen Receptor-Negative MDA-MB-435 Cells", Biochemical Pharmacology, Vol. 49, No. 3, pp. 351-358, 1995.	

Examiner Signature	<i>Megan Cotten</i>	Date Considered	4/21/2005
--------------------	---------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		O I P		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/734,638
Date Submitted: January 6, 2005 (use as many sheets as necessary)				Filing Date	12/15/2003
				First Named Inventor	Philippe ROUANET et al.
				Group Art Unit	Unassigned
				Examiner Name	1615
Sheet	3	of	3	Attorney Docket Number	029488-0113

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AM	B24	Ian S. FENTIMAN, "Tamoxifen and Mastalgia An Emerging Indication", Drugs 32 nd 477-480 (1986), pp. 477-480.			
AM	B25	Johannes GERDES et al., "CELL CYCLE ANALYSIS OF A CELL PROLIFERATION-ASSOCIATED HUMAN NUCLEAR ANTIGEN DEFINED BY THE MONOCLONAL ANTIBODY Ki-67 ^{1a} ", The Journal of Immunology, Vol. 133, No. 4, October 1984, pp. 1710-1715.			
AM	B26	J. GIRAUT et al., "Quantitative Measurement of 4-Hydroxy Tamoxifen in Human Plasma and Mammary Tumours by Combined Gas Chromatography/Negative Chemical Ionization Mass Spectrometry", Biological Mass Spectrometry, Vol. 22, (1993) pp. 395-402.			
AM	B27	Trisha GURA, "Cancer Models: Systems for Identifying New Drugs Are Often Faulty", Science, Vol. 278, November 7, 1997, pp. 1041-1042.			
AM	B28	Stanley G. KORENMAN et al., "ESTRADIOL RADIOIMMUNOASSAY WITHOUT CHROMATOGRAPHY: PROCEDURE, VALIDATION AND NORMAL VALUES", J. Clin. Endocrinol. Metab. 38:718-720 (1974).			
AM	B29	Catherine MALET et al., "Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of noram human breast epithelial (HBE) cells in culture", Journal of Steroid Biochemistry & Molecular Biology 82, (2002) pp. 289-296.			
AM	B30	Catherine S. MURPHY et al., "Structure-Function Relationships of Hydroxylated Metabolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro", Molecular Pharmacology, Vol. 38, No. 5, (1990), pp. 737-743.			
AM	B31	Mona NEMANI et al., "Activation of the human homologue of the Drosophila sine gene in apoptosis and tumor suppression", Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 9039-9042, August 1996.			
AM	B32	Y. NOMURA et al., "Effects of antiestrogens and medroxyprogesterone acetate on the clonogenic growth of tamoxifen-sensitive and resistant human breast cancer cells", Japanese Journal of Cancer Chemotherapy, 12(4), pp. 844-850 (1985)			
AM	B33	Naushin H. WASEEM et al., "Monoclonal Antibody Analysis of the Proliferating Cell Nuclear Antigen (PCNA) Structural conservation and the detection of a nucleolar form, Journal of Cell Science, 96, 121-129 (1990).			

Examiner Signature	<i>Allegant Cotton</i>	Date Considered	<i>4/21/2006</i>
--------------------	------------------------	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
Date Submitted: April 6, 2005					
(use as many sheets as necessary)					
Sheet	1	of	1		
				Attorney Docket Number	029488-0113

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
AVN	C1	DE	38 36 862 A1	Schering AG	5/3/1990	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				

Examiner Signature	<i>Alexandria</i>	Date Considered	<i>4/21/2005</i>
--------------------	-------------------	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>Date Submitted: July 27, 2005</p> <p>(use as many sheets as necessary)</p>															
		<p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>10/734,638</td> </tr> <tr> <td>Filing Date</td> <td>12/15/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Philippe Rouane</td> </tr> <tr> <td>Group Art Unit</td> <td>1615</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>029488-0113</td> </tr> </table>		Application Number	10/734,638	Filing Date	12/15/2003	First Named Inventor	Philippe Rouane	Group Art Unit	1615	Examiner Name	Unassigned	Attorney Docket Number	029488-0113
Application Number	10/734,638														
Filing Date	12/15/2003														
First Named Inventor	Philippe Rouane														
Group Art Unit	1615														
Examiner Name	Unassigned														
Attorney Docket Number	029488-0113														
Sheet	1	of	1												

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	

Examiner Signature		Date Considered	4/21/2016
--------------------	---	-----------------	-----------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
Date Submitted: November 21, 2005 <i>(use as many sheets as necessary)</i>		Application Number	10/734,638
		Filing Date	12/15/2003
		First Named Inventor	Philippe Rouanet
		Group Art Unit	1815
		Examiner Name	Thurman Page
		Attorney Docket Number	029488-0113
Sheet	1	of	1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

NON-PATENT INFORMATION			T ⁶
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
<i>AM</i>	E1	BRISSON, J., et al., "Tamoxifen and Mammographic Breast Densities, Cancer Epidemiology, Biomarkers & Prevention, Vol. 9, pp. 911-915 (2000).	
<i>AM</i>	E2	"High Breast Density a Risk Factor", pp. 1-4, http://www.breastcancer.org/research_genetics_091902_pf.html (8/11/05)	
<i>AM</i>	E3	PUJOL, H., et al., "Phase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue", Cancer Chemother Pharmacol, vol. 36, pp. 493-498 (1995).	

Examiner Signature		Date Considered	
-----------------------	---	--------------------	---

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.